The FDA approval of satralizumab for thyroid eye disease was based on data from the global phase 3 SatraGO program, which enrolled 258 patients across 19 countries

552c7ae14Space

Health

Health news, debates, and claims covering public health, mental health, nutrition, medical care, and health policy.

1 debate·6,984 claims·43 news stories

0